Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.

These shares are 'priced for awful'
Markets

These shares are 'priced for awful'

Kathmandu, SkyCity and Fletcher shares are under pressure. Some are taking the plunge.

NZ sharemarket drifts lower
Markets Market close

NZ sharemarket drifts lower

The S&P/NZX 50 Index closed at 11,776.73, easing 12.65 points or 0.11%.

Graham Skellern 02 Jul 2024